Table 2.

Univariate analysis of risk factors for overall survival among 580 patients with SM

VariablesAll patients univariate P (n = 580)ISM univariate P (n = 291)Advanced SM univariate P (n = 289)
Median age <.001 <.001 <.001 
Age >60 y <.001 <.001 <.001 
Males <.001 .4 .17 
Anemia sex adjusted <.001 <.001 <.001 
 n eval = 574 n eval = 285 
Leukocyte count <.001 .3 .03 
 n eval = 573 n eval = 284 
Platelet count <.001 .4 <.001 
 n eval = 567 n eval = 280 n eval = 287 
Platelet count <150 × 109/L <.001 .08 <.001 
 n eval = 567 n eval = 280 n eval = 287 
Urticaria pigmentosa <.001 .7 <.001 
 n eval = 577 n eval = 288 
Mast cell mediator symptoms <.001 .009 .68 
 n eval = 349 n eval = 153 n eval = 196 
Palpable hepatomegaly <.001 .03 .01 
 n eval = 579 n eval = 288 
Palpable splenomegaly <.001 .006 <.001 
 n eval = 578 n eval = 290 n eval = 288 
Serum albumin <.001 .4 <.001 
 n eval = 389 n eval = 157 n eval = 232 
Serum albumin <3.5 g/dL <.001 .2 .01 
 n eval = 389 n eval = 157 n eval = 232 
Serum ALP <.001 <.001 <.001 
 n eval = 547 n eval = 269 n eval = 278 
Serum ALP > UNL <.001 .001 <.001 
 n eval = 547 n eval = 269 n eval = 278 
KITD816V .4 .1 .16 
 n eval = 357 n eval = 172 n eval = 185 
ASXL1 mutated <.001 No adverse mutations <.001 
 n eval = 150  n eval = 107 
RUNX1 mutated .03 No adverse mutations .05 
 n eval = 150  n eval = 107 
NRAS mutated .002 No adverse mutations <.001 
 n eval = 150  n eval = 107 
Adverse mutations <.001 No adverse mutations <.001 
 n eval = 150  n eval = 107 
Abnormal karyotype <.001 .3 <.001 
 n eval = 53 n eval = 8 n eval = 45 
VariablesAll patients univariate P (n = 580)ISM univariate P (n = 291)Advanced SM univariate P (n = 289)
Median age <.001 <.001 <.001 
Age >60 y <.001 <.001 <.001 
Males <.001 .4 .17 
Anemia sex adjusted <.001 <.001 <.001 
 n eval = 574 n eval = 285 
Leukocyte count <.001 .3 .03 
 n eval = 573 n eval = 284 
Platelet count <.001 .4 <.001 
 n eval = 567 n eval = 280 n eval = 287 
Platelet count <150 × 109/L <.001 .08 <.001 
 n eval = 567 n eval = 280 n eval = 287 
Urticaria pigmentosa <.001 .7 <.001 
 n eval = 577 n eval = 288 
Mast cell mediator symptoms <.001 .009 .68 
 n eval = 349 n eval = 153 n eval = 196 
Palpable hepatomegaly <.001 .03 .01 
 n eval = 579 n eval = 288 
Palpable splenomegaly <.001 .006 <.001 
 n eval = 578 n eval = 290 n eval = 288 
Serum albumin <.001 .4 <.001 
 n eval = 389 n eval = 157 n eval = 232 
Serum albumin <3.5 g/dL <.001 .2 .01 
 n eval = 389 n eval = 157 n eval = 232 
Serum ALP <.001 <.001 <.001 
 n eval = 547 n eval = 269 n eval = 278 
Serum ALP > UNL <.001 .001 <.001 
 n eval = 547 n eval = 269 n eval = 278 
KITD816V .4 .1 .16 
 n eval = 357 n eval = 172 n eval = 185 
ASXL1 mutated <.001 No adverse mutations <.001 
 n eval = 150  n eval = 107 
RUNX1 mutated .03 No adverse mutations .05 
 n eval = 150  n eval = 107 
NRAS mutated .002 No adverse mutations <.001 
 n eval = 150  n eval = 107 
Adverse mutations <.001 No adverse mutations <.001 
 n eval = 150  n eval = 107 
Abnormal karyotype <.001 .3 <.001 
 n eval = 53 n eval = 8 n eval = 45 

Bold indicates statistical significance (P < .05).

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal